Chateal Eq Kit
NDC Package 50102-230-23

11-digit billing NDC: 50102023023 · Billing unit: EA · 3 EA per package
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Chateal Eq (levonorgestrel and ethinyl estradiol) kits is chateal EQ is indicated for use by females of reproductive potential to prevent pregnancy. This formulation utilizes a kit delivery system. Marketed by Afaxys Pharma, Llc, this product is identified by NDC 50102-230 and is authorized under FDA application ANDA206866.

Identification & Billing

NDC Package Code
50102-230-23
Package Description
3 POUCH in 1 CARTON / 1 BLISTER PACK in 1 POUCH (50102-230-21) / 1 KIT in 1 BLISTER PACK
Product Code
50102-230
11-Digit Billing Format
50102023023
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
3 EA
RxNorm Crosswalk
  • RxCUI: 1364848 - {21 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack [Chateal 28 Day]
  • RxCUI: 1364848 - Chateal 28 Day Pack
  • RxCUI: 238019 - levonorgestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet
  • RxCUI: 238019 - ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet
  • RxCUI: 748797 - inert 1 MG Oral Tablet

Clinical Specifications

Proprietary Name
Chateal Eq
Non-Proprietary Name
Levonorgestrel And Ethinyl Estradiol
Dosage Form
Kit - A packaged collection of related material.
Usage Information
Chateal EQ is indicated for use by females of reproductive potential to prevent pregnancy.

Regulatory & Marketing

Labeler Name
Afaxys Pharma, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA206866
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-23-2016
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50102-230-23 identifies a specific commercial package of 3 pouch in 1 carton / 1 blister pack in 1 pouch (50102-230-21) / 1 kit in 1 blister pack of Chateal Eq, a human prescription drug labeled by Afaxys Pharma, Llc. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Afaxys Pharma, Llc on September 23, 2016. The current certification is valid through December 31, 2027.

How is this Afaxys Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50102023023. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 3 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
50102-230-23
11-Digit CMS (5-4-2)
50102-0230-23

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.